MedPath
FDA Approval

ROBAXIN

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
January 18, 2024
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Methocarbamol(100 mg in 1 mL)

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Hikma Pharmaceuticals USA Inc.

Hikma Pharmaceuticals USA Inc.

946499746

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

ROBAXIN

Product Details

NDC Product Code
0641-6103
Application Number
NDA011790
Marketing Category
NDA (C73594)
Route of Administration
INTRAMUSCULAR, INTRAVENOUS
Effective Date
January 18, 2024
HYDROCHLORIC ACIDInactive
Code: QTT17582CBClass: IACT
Code: 125OD7737XClass: ACTIBQuantity: 100 mg in 1 mL
POLYETHYLENE GLYCOL 300Inactive
Code: 5655G9Y8AQClass: IACTQuantity: 0.5 mL in 1 mL
WATERInactive
Code: 059QF0KO0RClass: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32IClass: IACT
© Copyright 2025. All Rights Reserved by MedPath